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Abstract 
Background: In Senegal, a significant decrease of malaria transmission intensity has been noted the last years. 
Parasitaemia has become lower and, therefore, more difficult to detect by microscopy. In the context of submicro-
scopic parasitaemia, it has become relevant to rely on relevant malaria surveillance tools to better document malaria 
epidemiology in such settings. Serological markers have been proposed as an essential tool for malaria surveillance. 
This study aimed to evaluate the sero-epidemiological situation of Plasmodium falciparum malaria in two sentinel sites 
in Senegal.
Methods: Cross-sectional surveys were carried out in Velingara (south Senegal) and Keur Soce (central Senegal) 
between September and October 2010. Children under 10 years old, living in these areas, were enrolled using two-
level, random sampling methods. P. falciparum infection was diagnosed using microscopy. P. falciparum antibod-
ies against circumsporozoite protein (CSP), apical membrane protein (AMA1) and merozoite surface protein 1_42 
(MSP1_42) were measured by ELISA method. A stepwise logistic regression analysis was done to assess factors associ-
ated with P. falciparum antibodies carriage.
Results: A total of 1,865 children under 10 years old were enrolled. The overall falciparum malaria prevalence was 
4.99% with high prevalence in Velingara of 10.03% compared to Keur Soce of 0.3%. Symptomatic malaria cases (fever 
associated with parasitaemia) represented 17.37%. Seroprevalence of anti-AMA1, anti-MSP1_42 and anti-CSP antibody 
was 38.12, 41.55 and 40.38%, respectively. The seroprevalence was more important in Velingara and increased with 
age, active malaria infection and area of residence.
Conclusion: The use of serological markers can contribute to improved malaria surveillance in areas with declining 
malaria transmission. This study provided useful baseline information about the sero-epidemiological situation of 
malaria in Senegal and can contribute to the identification of malaria hot spots in order to concentrate intervention 
efforts.
Trial registration number: PACTR201305000551876 (http://www.pactr.org).
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Background
Despite increasing efforts to control malaria and many 
African countries reporting a decrease of malaria burden 
in recent years, the disease is still a major public health 
problem in many sub-Saharan African countries. Accord-
ing to the World Health Organization, there were an 
estimated 207 million malaria cases and 627,000 malaria 
deaths in the world in 2012. This situation justifies the 
need to strengthen malaria control strategies including: 
(1) clinical case management of malaria cases using rapid 
diagnostic test (RDTs) and artemisinin combination 
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therapy (ACT); (2) universal coverage of long-lasting, 
insecticide-treated nets (LLINs); (3) indoor residual 
spraying (IRS); and, (4) intermittent preventive treatment 
[1–3]. In Senegal, the National Malaria Control Pro-
gramme (NMCP) initiated the scaling-up of malaria con-
trol measures in 2005. Significant reduction of malaria 
morbidity has been noted these last years from 35.72% 
in 2001 to 5.62% in 2008 and 3.07% in 2009 [4]. Malaria 
parasitaemia has become lower and therefore more diffi-
cult to detect by microscopy with an increase in the pro-
portion of individuals carrying submicroscopic malaria 
parasites [5]. This may induce some limitation in malaria 
surveillance using microscopy. To overcome this issue, 
there is a need to develop innovative malaria surveillance 
tools that are more sensitive and more reliable for better 
documentation of malaria epidemiology. For this pur-
pose, serology is proposed as a reliable and sensitive tool 
to assess malaria epidemiology as well as malaria inter-
vention impact on malaria burden and transmission [6–
8]. Several Plasmodium falciparum antigens have been 
studied to assess malaria transmission and impact on the 
host immunity. To assess the level of malaria transmis-
sion, a pre-erythrocytic-stage antigen most commonly 
used is the circumsporozoite protein (CSP) with a short 
estimated half-life. Antibodies against this protein are 
correlated to transmission intensity and exposure dura-
tion, but not necessarily to plasmodial infections. This 
protein is labile and disappears quickly in the absence of 
exposure. P. falciparum erythrocytic-stage antigens, such 
as merozoite surface protein 1 (MSP) and apical mem-
brane antigen (AMA1) with long half-lives, reflect the 
cumulative exposure to malaria and can be used as an 
indicator of the burden of malaria [6, 7].
The analysis of immune responses against pre-erythro-
cytic-stage antigen (CSP) and erythrocytic-stage antigens 
(MSP and AMA1) can contribute to assess malaria trans-
mission and the impact on host immunity. This study was 
conducted to evaluate the sero-epidemiological situation 
of falciparum malaria using CSP, AMA1 and MSP1_42 




This study was carried out in two health districts (Velin-
gara and NDoffane) with a different endemicity level. 
Velingara health district is located in the southeastern 
part of Senegal, 500 km from the capital city of Dakar. In 
this district the study was conducted in Bonconto health 
post, which is headed by a nurse and has eight functional 
health huts staffed with community health workers, 
serving a population of 10,016 inhabitants. Ndoffane 
is located in the central part of Senegal, 200  km from 
Dakar. In this district the study was conducted in Lamar-
ame health post. This health post is led by a nurse and 
comprises 49 functional health huts and serves a popu-
lation of 20,000 inhabitants. In both study areas malaria 
transmission is seasonal, occurring during the rainy 
season (from July to November) with a peak in between 
October to November. P. falciparum is the most predom-
inant parasite species. These two areas are part of NMCP 
sentinel sites. Malaria control strategies implemented 
by the NMCP in both sites were represented by the 
case management of uncomplicated malaria cases using 
rapid diagnostic tests (RDTs) and artemisinin combina-
tion therapy (ACT); intermittent preventive treatment in 
pregnant women; universal coverage of LLINs. The IRS is 
applied only in Velingara.
Study design and population
A cross-sectional survey was conducted in Velingara and 
Keur Soce in September and October 2010, several years 
after the implementation of malaria control measures. 
Children under 10  years old, living in the area or who 
stayed at the site for at least 6  months and whose par-
ents or legal representatives gave informed consent form 
approval, were enrolled in the study using a two-level, 
random sampling method. Subjects whose parents or 
legal representatives did not give informed consent were 
excluded from the study.
Data collection method
An informed consent questionnaire was administered 
to collect individual data on socio-demographic (age, 
gender, weight, height, area of residence, bed net use). 
Weight and height were collected to determine nutri-




For each enrolled participant, three drops of blood were 
collected for thick and thin smear tests for the detec-
tion of malaria prevalence using microscopy. Slides were 
stained for 15 min with a 10% Giemsa solution. Parasite 
density was evaluated by counting the number of asexual 
parasites per 200 white blood cells (WBCs) and estimated 
by number of parasite per μl using the following formula: 
number of parasites × 8,000/200 assuming a WBC count 
8,000 cells/µl. Thick and thin smears were considered as 
negative after 100-field microscopic reading without any 
parasites being detected.
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Serological assessment
Malaria antigens
Apical membrane antigen (AMA1) was from the Pichia 
pastoris expressed ectodomain of P. falciparum FVO 
strain comprised amino acids 25–545 [9] (Donated by 
Dr Daniel Dodo, Noguchi Memorial Institute for Medical 
Research, University of Ghana, Legon, Ghana).
MSP1_42 protein was from the C-terminal MSP1_42 
amino acid sequence of the Uganda-Palo Alto (FUP) P. 
falciparum isolate (GenBank Accession No. M37213) 
expressed in Escherichia coli (Ec) system. The recombi-
nant protein, EcMSP1_42-FUP (Uganda-Palo Alto strain), 
represents the 33 kDa fragment from the 3D7 P. falcipa-
rum variant and the E-K-NG point mutations identified 
in the 19 kDa fragment within the MSP1_42 native mol-
ecule [10].
CSP was a full-length protein expressed in an Escheri-
chia coli system containing amino-acids Leu19 to Ser411 
(Indian isolate, GenBankTM No: AAN87606) [11].
MSP1_42 and CPS were donated by Dr Patrick Duffy 
and Dr Richard Shimp from NIH/NIAID (National Insti-
tutes of Health/National Institute of Allergy and Infec-
tious Diseases).
Enzyme‑linked immunosorbent assay (ELISA)
Three drops of blood were collected onto Whatman 
3MM filter paper, which was sealed and stored dry with 
desiccant at room temperature. Reconstituted sera were 
obtained from filter paper bloods spots described pre-
viously [12, 13]. Sera were tested for anti-MSP1_42 IgG 
antibodies, anti-AMA1 IgG antibodies and anti-CSP 
antibodies by indirect ELISA. Samples were also tested 
on freeze thawed P. falciparum schizont extract (con-
centration of 1 × 108/ml), which was coated onto ELISA 
plates at 1/500.
Briefly, 96 well ELISA plates were coated with 
100 µl/well of 0.1 μl/well of MSP1_42 and CSP antigens 
and 0.026  μl/well of AMA1 in coating buffer (1.59  g 
Na2CO3, 2.93  g NaHCO3, 1 liter distilled water, pH 
9.4). The plates were incubated overnight at 4°C. After 
incubation, plates were washed at three times using 
PBS (5.7  g NaH2PO4, 16.7  g Na2HPO4, 85  g NaCl in 
1  l distilled water) plus 0.05% Tween 20 (PBS/T) and 
blocked with 1% (w/v) skimmed milk power in PBS/T 
for 1  h at 37°C. Eluates were removed from 4°C just 
before use. After three more washes, eluates were 
diluted at a ration 1/100 in PBS/T and added 200 µl in 
duplicate in a well plate.
For each plate three types of control were used: deep 
well without serum but with a second antibody to meas-
ure the non-specific binding, pool of sera from patients 
with P. falciparum malaria (positive control) and pool of 
sera from non-infected subjects (negative control) from 
Copenhagen. Three washes were performed before incu-
bation for 1 h at 37° with secondary antibody (100 µl of 
horseradish peroxidase-conjugated rabbit anti-human 
IgG, SouthernBiotech ®). After incubation for 1  h at 
37°C, plates were developed with TMB/E (Upstate®, 
Chemicon® et Linco®, Millipore) as substrate for 30 min 
at room temperature in the absence of light and the reac-
tion was stopped by the addition of 50  µl/well of 2  M 
H2SO4. Optical density was read at 450  nm against a 
620 nm with an ELISA TECAN SUNRISE reader.
Haematological assessment
One drop of blood was collected from all participants for 
haemoglobin (Hb) level measurement using Hemo-Cue 
machine (HemoCue® Hb 301). Anaemia was defined as 
Hb concentration below 11 g/dl.
Statistical methods
After data collection, date entry work was performed 
using Excel software. Thereafter, analysis was carried out 
using Stata software version IC 12 software.
For serological assessment, the optical density was 
obtained by subtracting the average OD (Optical density) 
of duplicate wells from that of the corresponding blank 
wells. Values were converted into arbitrary units (AUs), 
as follows [14]:
To assess the nutritional status, data were transferred 
into Epi Info 3.04 d. The Z-scores for weight-for-age 
(underweight) and height-forage (stunting) were derived 
using Epinut Anthropometry. Children with Z-scores 
below—2 standard deviation (SD) of the National Cen-
tre for Health Statistic (NCHS), United States reference 
population median were considered to be malnourished.
Quantitative variables were described in terms of 
means, SD. Inter-group comparisons were done using 
ANOVA test or Student t test where appropriate, oth-
erwise non-parametric tests such as Mann–Whitney or 
Kruskal–Wallis were used.
For descriptive data, percentage was used to each out-
come. Antibodies seroprevalence was calculated and 
expressed by percentage with their 95% confidence inter-
vals. Proportions were compared using Chi square test 
or the Fisher exact test (univariate analysis). A stepwise 
logistic regression analysis was done to assess factors 
associated with P. falciparum antibodies carriage. Signifi-
cance level of the different tests was set at 5%.
Ethical considerations
The study was nested into a cluster-randomized trial 
[15] which had been approved by the Senegalese 
AU = 100×
[
Ln(OD test sample)− Ln(OD negative control)
Ln(OD positive control)− Ln(OD negative control)
]
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National Ethical Committee (Conseil National d’Ethique 
et de Recherche en Santé) and registered at the Pan 
African Clinical Trial Registry: registration num-
ber: PACTR201305000551876. In the field, individual 
informed consent was required prior to each participant 
enrolment. Community sensitization was done prior to 
the study to explain the planned investigations.
Results
Study participant characteristics
A total of 1,865 participants were studied (866 from 
Velingara and 999 from Keur Soce). The mean age of the 
study population was 4.24 ± 2 years. The study popula-
tion was mainly represented by children under 5  years 
old (53.62%). A proportion of 7.83% were less than 1 year 
old. Children over 5  years represented 38.55%. The sex 
ratio was 1.03. The mean Hb level was 9.93  ±  3.3  g/dl 
and was lower in Velingara (8.5 ±  3.4 g/dl). The overall 
prevalence of anaemia (Hb <11 g/dl) was 72.39% with a 
higher proportion in Keur Soce (77.14%) than in Velin-
gara 68.27% (p < 10−3).
The prevalence of stunting, underweight and wast-
ing was respectively 35.44, 26.65 and 10.51%. Stunting 
was more frequent in Velingara population while under-
weight and wasting were higher in Keur Soce. Study par-
ticipants characteristics are summarized in Table 1.
Malariaometric indices
Overall, the coverage rate of bed net use was 82.84%. The 
coverage rate of bed net was more higher in Velingara 
(95.41%) while in Keur Soce it was 72.07%. The propor-
tion of subjects with fever (axillary temperature ≥37.5°C) 
at the time of survey was 20.4 and 14.71% in Velingara 
and Keur Soce, respectively. Overall Plasmodium falcipa-
rum malaria prevalence was 4.99% [95% CI (4.02–6.1)]. 
Malaria prevalence was higher in Velingara at 10.03% 
[95% CI (8.3–12.7)] (90/866) than in Keur Soce, where 
it was 0.3% [95% CI (0.06–0.8)] (3/999). Among children 
with falciparum malaria, 17.37% had fever providing an 
odds ratio at 1.81 [95% CI (1.13–2.91)] (Table 2).
The mean production of anti-AMA1 antibody was 16.04 
AU and varied from 16.59 AU in Velingara to 15.57 AU in 
Keur Soce. No significance difference was noted between 
the two sites (p = 0.57). MSP1_42 and CSP antibodies was 
15.17 AU and 29.25 UA, respectively; both were higher in 
Velingara’s population (p  <  10−3). Antibodies production 
was significantly higher among children with P. falciparum 
infection compared to non-infected children (Table 3).
The overall seroprevalence rate of anti-AMA1, anti-
MSP1_42 and anti-CSP antibodies was at 38.12% [95% 
CI (35.37–41.03)], 41.55% [95% CI (38.68–44.58)] and 
40.38% [95% CI (37.54–43.36)], respectively. The sero-
prevalence of these antibodies was higher in Velingara 
compared to Keur Soce (p < 10−3) (Figure 1).
Multivariate logistic regression analyses revealed that 
seroprevalence increased with age, active malaria infec-
tion and area of residence. In children over 5 years old, 
the seroprevalence of anti-AMA1 antibody was 46.1% 
[ORa = 1.18; IC (0.8–1.73), p value = 0.43] and this was 
more important among female children (38.7%), subjects 
with stunting (37.97%) and subjects without anaemia 
(43.88%). Seroprevalence of anti-AMA1 antibody was 
higher in subjects with P. falciparum infection 40.86% 
[ORa = 1.13; IC (0.74–1.72); p value = 0.56] and in sub-
jects living in Velingara 46.3% [ORa  =  1.85; IC (1.58–
2.32); p  <  10−3]. The seroprevalence of anti-MSP1_42 
antibody was 37.3% [ORa  =  1.05; IC (0.73–1.51); p 







Mean age (year) 4.24 ± 2 4.5 ± 2.7 3.87 ± 1.9
Age group (year)
 <1 146 (7.83%) 86 (58.9%) 60 (41.01%)
 1–4 1000 (53.62%) 344 (34.4%) 656 (65.67%)
 5–10 719 (38.55%) 436 (60.64%) 283 (28.33%)
Gender
 Female 917 (49.17%) 443 (51.15%) 474 (47.45%)
 Male 948 (50.83%) 423 (48.85%) 525 (52.55%)
Hb mean (g/dl) 9.93 ± 3.3 8.5 ± 3.4 10.16 ± 4.2
Anemia (Hb <11 g/dl)
 Yes 1350 (72.39%) 668 (77.14%) 682 (68.27%)
 No 515 (27.61%) 198 (22.86%) 317 (31.73%)
Stunting
 Yes 661 (35.44%) 379 (43.76%) 282 (28.23%)
 No 1204 (64.56%) 487 (56.24%) 717 (71.77%)
Underweight
 Yes 497 (26.65%) 214 (24.71%) 283 (28.33%)
 No 1368 (73.35%) 652 (75.29%) 716 (71.67%)
Wasting
 Yes 196 (10.51%) 47 (5.43%) 149 (14.91%)
 No 1669 (89.49%) 819 (94.57%) 850 (85.09%)








 Yes 1.545 (82.84) 852 (95.41%) 720 (72.07%)
 No 320 (17.16) 41 (4.59%) 279 (27.93%)
Fever
 Yes 324 (17.37%) 177 (20.4%) 147 (14.71%)
 No 1541 (82.63%) 689 (79.56%) 852 (85.29%)
Pf malaria prev-
elance
93 (4.99%) 90 (10.3%) 3 (0.3%)
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value =  0.8] in children under 5  years old while it was 
more important in children over 5  years old 47.57% 
[ORa = 1.28; IC (0.87–1.87), p value = 0.43].
For children with malaria infection, the seroprevalence 
of anti-MSP1_42 antibody was 52.69% [ORa  =  1.01; IC 
(0.65–1.55); p value  =  0.95]. For children over 5  years, 
the seroprevalence of anti-CSP antibody was 43.53% 
[ORa  =  1.08; IC (0.75–1.56); p  =  0.66] compared to 
other children. Anti-CSP antibody was more important 
in female children (41%), children with stunting 43.72% 
[ORa = 1.09; IC (0.85–1.4); p = 0.45] and children with 
anaemia (40.44%). The prevalence of anti-CSP antibody 
was associated with active malaria infection. Prevalence 
of anti-CSP antibody was more important in children 
with malaria infection 46.24% [ORa = 1.2; IC (0.78–1.84); 
p = 0.4]. The prevalence of anti-CSP antibody was more 
important in Velingara 52.66% [ORa  =  2.63; IC (2.13–
3.24); p < 10−3] compared to Keur Soce (29.73%). There 
is no correlation between seroprevalence of antibody and 
sex (Tables 4, 5, 6).
Discussion
In Senegal malaria is still a leading cause of morbidity and 
mortality. These last years, the combination of malaria 
control measures has helped to reduce malaria burden. 
This has led the country to outline a vision of malaria 
elimination. To address this issue, new approaches are 
fundamental for a better characterization of malaria epi-
demiology in the areas of reduced transmission. Serol-
ogy has been proposed as a sensitive and reliable tool for 
malaria epidemiology assessment [16–19].
This study was conducted to assess the sero-epide-
miological situation of malaria in two sentinel sites 
with different epidemiological profiles in Senegal. The 
study showed a low prevalence of malaria parasitaemia, 
although P. falciparum carriage was significantly higher 
in the southern part of the country (Velingara). How-
ever, anaemia remained high in both sites. These data 
Table 3 Mean production of anti-AMA1, anti-MSP1_42 and anti-CSP antibodies
Total (N = 1,865) Velingara (N = 866) Keur Soce (N = 999) p value
General mean (AU) Mean (AU) IC (95%) Mean (AU) IC (95%)
AMA1 16.04 16.59 14.3–18.8 15.57 12.8–18.3 0.57
MSP1_42 15.17 21.7 19.1–24.3 9.5 8.2–10.7 <10
−3
CSP 29.25 48.2 40.1–56.4 12.7 11.5–13.9 <10−3
AMA1 MSP1 CSP
Vélingara 46.3 53.12 52.66





















Figure 1 Seroprevalence of anti-CSP, anti-AMA1 and anti-MSP1_42 
antibody in Velingara and Keur Soce site. Seroprevalence of IgG anti-
body to different malaria antigens (AMA1, MSP1_42, and CSP). AMA1 
(Apical Membrane Protein), MSP1_42 (Merozoite Surface Protein) and 
CSP (Circumsporozoite Protein). Black Velingara site (southern part of 
Senegal) and grey Keur Soce site (central part of Senegal). χ2 test was 
done to compare proportions of antibody responders between two 
sites. Proportion of seropositive was more important in Velingara site 
compared to Keur Soce site (p < 10−3).











 <1 57 (39.1%) 1 1
 1–4 322 (32.2%) 0.74 (0.5–1.06) 0.82 (0.56–1.18) 0.28
 5–10 332 (46.1%) 1.34 (0.93–1.92) 1.18 (0.8–1.73) 0.43
Gender
 Female 355 (38.7%) 1 1
 Male 356 (37.5%) 0.95 (0.79–1.14) 0.97 (0.81–1.18) 0.82
Nutritionnel status
 Stunting 251 (37.97%) 0.99 (0.81–1.2) 0.94 (0.83–1.21) 0.62
 Underweight 182 (36.62) 0.92 (0.74–1.13) 0.97 (0.87–1.2) 0.79
 Wasting 62 (31.63%) 0.73 (0.53–0.99) 0.81 (0.57–1.15) 0.25
Anemia
 No 226 (43.88%) 1 1
 Yes 485 (35.93%) 0.72 (0.58–0.88) 0.72 (0.57–0.92) 0.005
Malaria parasite
 No 673 (37.98%) 1 1
 Yes 38 (40.86) 1.23 (0.74–1.72) 1.13 (0.74–1.72) 0.56
Residence area
 Keur Soce 310 (31.03%) 1 1
 Velingara 401 (46.30%) 1.92 (1.58–2.32) 1.85 (1.58–2.32) <10−3
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are consistent with results from national malaria indica-
tor surveys conducted 2008–2009, which showed similar 
patterns in terms of P. falciparum carriage and anaemia 
prevalence [20]. The national survey conducted in 2012 
and 2013 showed an overall prevalence of P. falciparum 
at 2.8% with disparities between the southern part (9.3%) 
and the central part (2.2%) of the country [21]. The dif-
ference in malaria prevalence between the two areas 
demonstrates once again the heterogeneity of malaria 
transmission in Senegal. This was demonstrated in Gam-
bia in 2008 and 2009 [22].
Similar results were found in 2005 with the heteroge-
neity of malaria in the east and west of Cambodia [23]. 
Despite the low prevalence of P. falciparum, anaemia was 
closely associated with malaria parasitaemia. Other stud-
ies demonstrated that the main factors influencing anae-
mia occurrence in the central and the southern parts of the 
country are mainly represented by P. falciparum carriage, 
malnutrition, sickle cell traits and alpha-thalassaemia [24].
The overall seroprevalence of AMA1, MSP1_42 and CSP 
antibodies was 38.12, 41.55 and 40.38%, respectively. Sig-
nificant difference between the two areas was observed 
with a higher seroprevalence in the southern part (Velin-
gara). Although the serological assessment confirmed 
malaria heterogeneity as shown by microscopy. Propor-
tion of P. falciparum carriage was significantly lower 
than antibodies level. These findings are in accordance 
with what were observed in Madagascar [6]. In Tanzania, 
similar results were noted with a high seroprevalence of 
antibodies against AMA1 (40.7%) and MSP1 (64.1%) [19]. 
Similar results were found in Ghana with high seropreva-
lence of AMA1 and CSP antibodies [25]. A high preva-
lence of PfMSP1 and PfAMA1 antibodies was found in 
Indonesia whatever the area and the season [26].
These results show that serology could be a good 
indicator for malaria surveillance. 5% of the total study 
participant was found positive by microscopy while anti-
bodies excretion increased by at least sixfolds. The study 
demonstrated that using microscopy alone for malaria 
surveillance could underestimate malaria burden, par-
ticularly in areas with reduced malaria transmission. 
These data are confirmed by other studies [6, 19, 23, 27].
The study showed that seroprevalence of AMA1, 
MSP1_42 and CSP antibodies increased with age, P. 
falciparum carriage and the area of residence. Similar 
results were found in Vanuatu in 2008 and in northern 
Peru between 2008 and 2010 [28, 29]. In 2002, a study 
in Ghana showed that the level of antibody was higher 
among older subjects [30]. This was also demonstrated 
in The Gambia and Senegal in 2002 [22, 31]. In chil-
dren with P. falciparum infection, the seroprevalence of 
antibodies is higher compared to those without P. falci-
parum infection. The association between malaria and 











 <1 60 (41.1%) 1 1
 1–4 373 (37.3%) 0.85 (0.59–61.21)1.05 (0.73–1.51) 0.8
 5–10 342 (47.57%) 1.3 (0.96–1.86) 1.28 (0.87–1.87) 0.19
Gender
 Female 385 (41.98%) 1 1
 Male 390 (41.14%) 0.96 (0.8–1.16) 0.98 (0.82–1.18) 0.87
Nutritional status
 Stunting 286 (43.27%) 1.15 (0.92–1.45) 0.97 (0.75–1.24) 0.8
 Underweight 205 (41.25) 0.93 (0.71–1.2) 0.93 (0.82–1.43) 0.59
 Retard  
staturo-
pondéral
75 (38.27%) 0.89 (0.64–1.24) 0.93 (0.67–1.29) 0.68
Anemia
 No 213 (41.36%) 1 1
 Yes 562 (41.63%) 1.02 (0.82–1.24) 0.99 (0.78–1.23) 0.86
Malaria parasite
 No 726 (40.97%) 1 1
 Yes 49 (52.69%) 1.6 (1.05–2.43) 1.01 (0.65–1.55) 0.95
Residence area
 Keur Soce 315 (31.53%) 1 1
 Velingara 460 (53.12%) 2.46 (2.04–2.97) 2.4 (1.95–2.95) <10−3











 <1 62 (42.47%) 1 1
 1–4 378 (37.8%) 0.82 (0.57–1.17) 0.85 (0.59–1.21) 0.38
 5–10 313 (43.53%) 1.04 (0.73–1.5) 1.08 (0.75–1.56) 0.66
Gender
 Female 376 (41%) 1 1
 Male 377 (39.77%) 0.95 (0.78–1.14) 0.98 (0.81–1.19) 0.86
Nutritional status
 Stunting 289 (43.72%) 1.24 (1.02–1.5) 1.09 (0.85–1.4) 0.45
 Underweight 191 (38.43%) 0.89 (0.72–1.1) 0.88 (0.64–1.09) 0.19
 Wasting 55 (28.06%) 0.54 (0.4 0.75) 0.61 (0.43–0.86) 0.005
Anemia
 No 207 (40.19%) 1 1
 Yes 546 (40.44%) 1.01 (0.82–1.24) 0.87 (0.69–1.1) 0.25
Malaria parasite
 No 710 (40.07%) 1 1
 Yes 43 (46.24%) 1.28 (0.085–1.95) 1.2 (0.78–1.84) 0.4
Residence area
 Keur Soce 297 (29.73%) 1 1
 Velingara 456 (52.66%) 2.63 (2.17–3.17) 2.63 (2.13–3.24) <10−3
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level of antibody (anti-AMA1, anti-MSP1_42 and anti-
CSP) has been demonstrated by several immuno-epide-
miological studies [32–39]. Comparing both sites, the 
seroprevalence of antibodies is higher in Velingara than 
in Keur Soce. This may be due to the fact that malaria 
transmission is most intense in southern Senegal. The 
variation of malaria between areas has been demon-
strated [22].
Gender, Hb level and nutritional status did not play a 
role in antibody production. This was demonstrated in 
2002 in Senegalese preschool children when assessing the 
immunological consequences of intermittent preventive 
treatment [30].
Serological markers can be a useful tool for malaria 
epidemiology characterization particularly in areas 
with a decrease of malaria and can even contribute to 
the identification of malaria hot spots in order to con-
centrate intervention efforts. Others studies suggest 
that sero-epidemiological analysis will be useful tool in 
assessing short-term changes in exposure and malaria 
transmission in area with a low or seasonal transmission. 
It was demonstrated in Ghana, Kenya and Indonesia [40, 
41].
Study limitation
The age of the study population being limited to 10 years 
constituted a study limitation. To better document the 
changing profile of malaria epidemiology, it would be rel-
evant to extend the study to the other age groups in order 
to characterize the burden of the disease in the study 
areas.
Conclusion
Serological markers can be used as complementary tools 
for malaria survey in areas with a declining pattern of 
malaria in Senegal. This study provided useful baseline 
information about the sero-epidemiological situation of 
malaria in Senegal and can contribute to the identifica-
tion of malaria hot spots in order to concentrate inter-
vention efforts.
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